ArticleBMC medical ethics2016
Conceptual and terminological confusion around personalised medicine: a coping strategy.
Article in BMC medical ethics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Exploring interdisciplinary perspectives on the implementation ofJournal of Alzheimer's disease : JAD · 2025Article
- Exploring healthcare personnel's knowledge, barriers, and innovative approaches in personalised oncology medicine: a scoping review.Critical public health · 2025Review
- The Use of Big Data in Personalized Healthcare to Reduce Inventory Waste and Optimize Patient Treatment.Journal of personalized medicine · 2024Review
- Article
- Plastic diagnostics: The remaking of disease and evidence in personalized medicine.Social science & medicine (1982) · 2022Article
- Methods for Stratification and Validation Cohorts: A Scoping Review.Journal of personalized medicine · 2022Article
- Representations of personalised medicine in family medicine: a qualitative analysis.BMC primary care · 2022Article
- The prospects of precision psychiatry.Theoretical medicine and bioethics · 2021Article
- Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview.Molecular diagnosis & therapy · 2021Review
- The personalized medicine discourse: archaeology and genealogy.Medicine, health care, and philosophy · 2021Article
- Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.HemaSphere · 2021Review
- Knowledge repositories. In digital knowledge we trust.Medicine, health care, and philosophy · 2020Article
- Genetic Signatures of Drug Response Variability inGenetics · 2019Article
- Evidence for personalised medicine: mechanisms, correlation, and new kinds of black box.Theoretical medicine and bioethics · 2019Article
- Contested futures: envisioning "Personalized," "Stratified," and "Precision" medicine.New genetics and society · 2019Article
- Improving Community Advisory Board Engagement in Precision Medicine Research to Reduce Health Disparities.Journal of health disparities research and practice · 2019Article
- I'veInternational journal of molecular sciences · 2018Review
- Applying systems biology to biomedical research and health care: a précising definition of systems medicine.BMC health services research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe idea of personalised medicine (PM) has gathered momentum recently, attracting funding and generating hopes as well as scepticism. As PM gives rise to differing interpretations, there have been several attempts to clarify the concept. In an influential paper published in this journal, Schleidgen and colleagues have proposed a precise and narrow definition of PM on the basis of a systematic literature review. Given that their conclusion is at odds with those of other recent attempts to understand PM, we consider whether their systematic review gives them an edge over competing interpretations. DISCUSSION: We have found some methodological weaknesses and questionable assumptions in Schleidgen and colleagues' attempt to provide a more specific definition of PM. Our perplexities concern the lack of criteria for assessing the epistemic strength of the definitions that they consider, as well as the logical principles used to extract a more precise definition, the narrowness of the pool from which they have drawn their empirical data, and finally their overlooking the fact that definitions depend on the context of use. We are also worried that their ethical assumption that only patients' interests are legitimate is too simplistic and drives all other stakeholders' interests-including those that are justifiable-underground, thus compromising any hope of a transparent and fair negotiation among a plurality of actors and interests.
conclusionAs an alternative to the shortcomings of attempting a semantic disciplining of the concept we propose a pragmatic approach. Rather than considering PM to be a scientific concept in need of precise demarcation, we look at it as an open and negotiable concept used in a variety of contexts including at the level of orienting research goals and policy objectives. We believe that since PM is still more an ideal than an achieved reality, a plurality of visions is to be expected and we need to pay attention to the people, reasons and interests behind these alternative conceptions. In other words, the logic and politics of PM cannot be disentangled and disagreements need to be tackled addressing the normative and strategic conflicts behind them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.